Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNG2 | P59768 | 1/20 | 0.74 |
| ▸ | GNB1 | P62873 | 1/20 | 0.74 |
| ▸ | PRMT1 | Q99873 | 2/20 | 0.67 |
| ▸ | MAPT | P10636 | 6/20 | 0.55 |
| ▸ | MEN1 | O00255 | 5/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.55 |
| ▸ | RECQL | P46063 | 2/20 | 0.55 |
| ▸ | BLM | P54132 | 2/20 | 0.55 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.55 |
| ▸ | FTO | Q9C0B1 | 2/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.55 |
| ▸ | HTT | P42858 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | SMAD3 | P84022 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | USP2 | O75604 | 2/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | CDK2 | P24941 | 1/20 | 0.53 |
| ▸ | CHAT | P28329 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL328742 | 1.00 | GNG2 (0.74) | GNG2GNB1PRMT1MAPTMEN1 | |
| SCHEMBL6269753 | 0.99 | GNG2 (0.72) | GNG2GNB1PRMT1MAPTMEN1 | |
| SCHEMBL5356623 | 0.90 | PRMT1 (0.86) | GNG2GNB1PRMT1MAPTMEN1 | |
| SCHEMBL29756279 | 0.88 | FTO (0.73) | GNG2GNB1PRMT1MAPTMEN1 | |
| SCHEMBL5359408 | 0.88 | FTO (0.73) | GNG2GNB1PRMT1MAPTMEN1 | |
| SCHEMBL5352933 | 0.87 | PRMT1 (0.62) | GNG2GNB1PRMT1MAPTMEN1 | |
| SCHEMBL30408346 | 0.85 | GNG2 (1.00) | GNG2GNB1PRMT1MAPTMEN1 | |
| SCHEMBL29424349 | 0.85 | GNG2 (1.00) | GNG2GNB1PRMT1MAPTMEN1 | |
| SCHEMBL29942282 | 0.85 | GNG2 (1.00) | GNG2GNB1PRMT1MAPTMEN1 | |
| SCHEMBL334144 | 0.85 | GNG2 (1.00) | GNG2GNB1PRMT1MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 549 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026089857-A1 | METHOD OF PREPARING AND USING A SKIN CARE COMPOSITION | DOW SILICONES CORPORATION (US) | 2026-04-30 | — | — | WO | claimed |
| WO-2026089856-A1 | METHOD OF PREPARING AND USING A SKIN CARE FORMULATION | DOW SILICONES CORPORATION (US) | 2026-04-30 | — | — | WO | claimed |
| US-12576026-B2 | Formulations of nebivolol | EXTROVIS AG (CH) | 2026-03-17 | — | — | US | claimed |
| EP-4061326-B1 | PERSONAL CARE COMPOSITION COMPRISING A MULTISTAGE POLYMER | DOW GLOBAL TECHNOLOGIES LLC (US) | 2026-02-25 | — | — | EP | claimed |
| US-12453690-B2 | Aqueous suncare formulation | DOW GLOBAL TECHNOLOGIES LLC (US) | 2025-10-28 | — | — | US | claimed |
| EP-4216910-B1 | SKIN CARE FORMULATION | DOW GLOBAL TECHNOLOGIES LLC (US) | 2025-09-17 | — | — | EP | claimed |
| EP-4093514-B1 | AQUEOUS SUNCASE FORMULATION BASED ON SULFATED A CRYSTALLINE CELLULOSE SPF BOOSTER | DOW GLOBAL TECHNOLOGIES LLC (US) | 2025-08-06 | — | — | EP | claimed |
| EP-4590258-A1 | SKIN CARE FORMULATION | Dow Silicones Corporation (US) | 2025-07-30 | — | — | EP | claimed |
| US-12370134-B2 | Personal care formulation | DOW GLOBAL TECHNOLOGIES LLC (US) | 2025-07-29 | — | — | US | claimed |
| CN-119186647-A | Plasma enhanced Ag@AgCl/4, 5-dibromo fluorescein composite photocatalyst and preparation method thereof | 大连大学 | 2024-12-27 | — | — | CN | claimed |
| US-20240122840-A1 | PERSONAL CARE FORMULATION | DOW GLOBAL TECHNOLOGIES LLC | 2024-04-18 | — | — | US | claimed |
| US-20230310298-A1 | SKIN CARE FORMULATION | DOW GLOBAL TECHNOLOGIES LLC (US) | 2023-10-05 | — | — | US | claimed |
| EP-4216910-A1 | SKIN CARE FORMULATION | Dow Global Technologies LLC (US) | 2023-08-02 | — | — | EP | claimed |
| CN-113125422-B | Preparation method of chemiluminescent hydrogel microbead, prepared hydrogel microbead and application thereof | 合肥工业大学 | 2023-07-25 | — | — | CN | claimed |
| CN-116355437-A | Preparation method for improving saturation of bromofluorescein lake | 湖南金桥新材料科技有限公司 | 2023-06-30 | — | — | CN | claimed |
| US-20230034183-A1 | AQUEOUS SUNCARE FORMULATION | DOW GLOBAL TECHNOLOGIES LLC | 2023-02-02 | — | — | US | claimed |
| EP-4093514-A1 | AQUEOUS SUNCASE FORMULATION BASED ON SULFATED A CRYSTALLINE CELLULOSE SPF BOOSTER | Dow Global Technologies LLC (US) | 2022-11-30 | — | — | EP | claimed |
| EP-4061326-A1 | PERSONAL CARE COMPOSITION COMPRISING A MULTISTAGE POLYMER | Dow Global Technologies LLC (US) | 2022-09-28 | — | — | EP | claimed |
| WO-2022066592-A1 | SKIN CARE FORMULATION | DOW GLOBAL TECHNOLOGIES LLC (US) | 2022-03-31 | — | — | WO | claimed |
| US-11234910-B2 | Capsules comprising pigments, and method for producing same | AMOREPACIFIC CORPORATION (KR) | 2022-02-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240122840-A1 | PERSONAL CARE FORMULATION | F12, C1R, MC1R | GNG2 3539/4885GNB1 3633/4885PRMT1 37/4885 |
| US-12370134-B2 | Personal care formulation | F12, C1R, MC1R | GNG2 3539/4885GNB1 3633/4885PRMT1 37/4885 |
| US-12576026-B2 | Formulations of nebivolol | SI, SORD, SCNN1B | GNG2 4433/4885GNB1 1840/4885PRMT1 4234/4885 |
| US-20230310298-A1 | SKIN CARE FORMULATION | CUTA, KRT18, C1R | GNG2 4105/4885GNB1 3888/4885PRMT1 541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.